Strong, durable responses to selpercatinib in RET-driven medullary thyroid cancer

August 26, 2020

BOSTON - Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the gene RET, was effective in a clinical trial at shrinking tumors in patients with medullary thyroid cancer, with a majority of patients living for more than a year without disease progression.

The drug was effective both in patients with no prior treatment with targeted anti-cancer drugs and in those who had disease progression following treatment with other multitargeted agents, report Lori J. Wirth, MD, investigator in the Massachusetts General Hospital (MGH) Cancer Center, and colleagues.

"What we're seeing is a combination of very good efficacy and also very good tolerability with selpercatinib," says Wirth. "The response rates are high, responses are very durable, and overall the drug does not cause a lot of toxicity."

Wirth is the lead author of a study published in the New England Journal of Medicine reporting results of the phase 1/2 trial. The trial formed the basis for the approval of selpercatinib by the US Food and Drug Administration in May 2020 for adults and children 12 and older with advanced or metastatic RET-mutated medullary thyroid cancer who require systemic therapy, adults with metastatic RET-driven non-small cell lung cancer, and patients 12 and older with advanced or metastatic RET-fusion positive thyroid cancer resistant to radioactive iodine who require systemic therapy.

Selpercatinib is the first approved drug of its kind targeted specifically to cancers driven by mutations or alterations in the gene RET. Mutations in RET are responsible for up to 70 percent of medullary thyroid cancers (MTC), while RET gene fusions (abnormal combinations of parts of two different genes) account for one-to-two percent of all non-small cell lung cancers and ten-to-twenty percent of other thyroid cancers.

Physicians typically treat patients with RET-associated cancers with drugs that target RET and multiple other enzymes (kinases) commonly found in many different types of cancer. But the two multi-kinase inhibitors currently approved for treatment of medullary thyroid cancer, vandetanib and cabozantinib, have substantial off-target side effects that limit their use in patients with RET-driven cancers.

"If you have a clean, RET-specific inhibitor such as selpercatinib, then you can really pound down RET very strongly and hit the driver alteration much harder, with a better side effect profile," Wirth explains.

In the trial objective response rates, a measure of significant and clinically important tumor shrinkage, were 69 percent for patients with RET-mutated medullary thyroid cancers treated with selpercatinib who had previously received vandetanib, cabozantinib, or both; 73 percent in similar patients who had not received either of the other drugs; and 79 percent for patients with previously treated RET fusion-positive thyroid cancers.

In all, 82 percent of previously treated patients with medullary thyroid cancer, and 92 percent of patients who had not received either vandetanib or cabozantinib lived for at least one year without further disease progression.

The most common side effects with selpercatinib were high blood pressure, increased liver enzyme levels, decrease in sodium levels, and diarrhea, all of which were manageable. Only four of 162 patients had to stop selpercatinib because of side effects.

Wirth and colleagues have launched an international phase-three trial comparing selpercatinib with either vandetanib or cabozantinib as first-line therapy for RET-mutated medullary thyroid cancer.
-end-
Additional co-investigators include Jochen Lorch, MD, Dana-Farber Cancer Institute, Boston; Eric Sherman, MD and Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, NYC; Bruce Robinson, MD, Royal North Shore Hospital, St. Leonards, NSW and Benjamin Solomon MB, BS, PhD, Peter MacCallum Cancer Institute, Melbourne, VIC, Australia; Hyunseok Kang, MD, UC San Francisco; Jonathan W. Goldman, MD, UCLA; Viola W. Zhu, MD, UC Irvine; Francis Worden, MD, U Michigan, Ann Arbor; Nehal Lakhani, MD, PhD, START Midwest, Grand Rapids, MI; Marcia Brose MD, PhD U Pennsylvania, Philadelphia; Jyoti Patel, MD, U Chicago; Sophie Leboulleux, MD, Institut Gustave Roussy, Villejuif, Yann Godbert, MD, Institut Bergonie, Bordeaux, (Y.G.), Fabrice Barlesi, MD, PhD, Aix Marseille University, Christelle de la Fouchardiere, MD, Centre Leon Berard, Lyon, and Jacques Medioni, MD, PhD, Hopital Europeen Georges-Pompidou, all in France; John C. Morris, MD, Mayo Clinic, Rochester, MN; Taofeek K. Owonikoko, MD, PhD, Emory University, Atlanta; Daniel S.W. Tan, M.B., B.S, National Cancer Center Singapore; Oliver Gautschi, MD University of Bern, and Cantonal Hospital of Lucerne, Switzerland; Jared Weiss, MD UNC, Chapel Hill; Mark E. Burkard, MD, PhD, U Wisconsin, Madison; Janessa Laskin, MD, British Columbia Cancer Agency, Vancouver, Canada; Matthew H. Taylor, MD, OHSU, Portland; Matthias Kroiss, MD, Universitatsklinikum Wurzburg, Germany; Todd M. Bauer, MD Sarah Cannon Research Institute-Tennessee Oncology, Nashville; Benjamin Levy, MD, Johns Hopkins Kimmel Cancer Center, Washington, DC; Victor Moreno, MD, PhD, Fundacion Jimenez Diaz, Madrid, Spain; Kevin Ebata, PhD, Michele Nguyen, B.S., Dana Heirich, MSN, Edward Y. Zhu, PhD, Xin Huang, PhD, Luxi Yang, MS, Jennifer Kherani, MD, and S. Michael Rothenberg, MD, PhD, Loxo Oncology, Stamford, CT: Vivek Subbiah, MD and Maria E. Cabanillas, MD, UT MD Anderson Cancer Center, Houston; and Manisha H. Shah, MD, Ohio State University Comprehensive Cancer Center, Columbus.

The trial was supported by Loxo Oncology, a wholly owned subsidiary of Eli Lilly and Company. Dr. Wirth discloses a consulting or advisory role with Loxo Oncology, Eli Lilly and Company, and other companies.

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $1 billion and comprises more than 8,500 researchers working across more than 30 institutes, centers and departments. In August 2019 the MGH was named #6 in the nation by U.S. News & World Report in its list of "America's Best Hospitals."

Massachusetts General Hospital

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.